Bioavailability of Omega-3 fatty acids after a novel microencapsulation process

Phase 2

Completed

• Conditions: Bioavailability of different formulations of Omega-3 oil; Diet and Nutrition - Other diet and nutrition disorders

• Registration Number: ACTRN12612000634875
• Lead Sponsor: niversity of Queensland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-06-14
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 10

Inclusion Criteria

(i) Age 18-60 years
(ii) Healthy body weight (body mass index [BMI] 18.5-24.9 kg/m2), not overweight or obese (to improve likelihood of compliance with diet imposed the week prior)
(iii) Not currently taking omega-3 supplements
(iv) Available to participate for an entire day at 2 time points, 6 weeks apart

Exclusion Criteria

(i) BMI <18.5 or >24.9 kg/m2
(ii) Current infection
(iii) Current consumption of omega-3 supplements
(iv) Inability to provide informed consent due to diminished understanding or comprehension, or a language other than English spoken and an interpreter unavailable

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evels of DHA and EPA in plasma (mg/mL)[4 x baseline measures (3 days prior to and on the day of the trial starting). Intervention will be administered on the day of the trial. Measurements will be taken 2, 4, 6, 8, 24 hours after consumption of treatment one (1300mg EPA/DHA with the seaweed gel encapsulant) or treatment two (1300mg EPA/DHA without the seaweed gel encapsulant).]

Secondary Outcome Measures

Name	Time	Method
Tolerance questionnaire[day 5 of trial]